玻璃体切除术联合视网膜下组织型纤溶酶原激活剂及气体填充治疗黄斑中心凹下出血:预后因素与临床结局
回顾性非对照干预性病例系列纳入77例患者78只眼,84.6%眼黄斑中心凹下出血病因为年龄相关性黄斑变性;91.5%眼术后2个月内实现出血部分或完全移位,视力从术前20/1,449提高至平均随访6.3个月时20/390(P < 0.001)。预后较好与无年龄相关性黄斑变性(P = 0.02)及黄斑中心凹上方出血较少(P < 0.001)相关。
要点
- 84.6%眼黄斑中心凹下出血由年龄相关性黄斑变性引起,91.5%眼术后2个月内出血部分或完全移位。
- 视力从术前20/1,449提高至平均随访6.3个月时20/390,约相当于Snellen视力提高5行(P < 0.001)。
- 无年龄相关性黄斑变性(P = 0.02)及黄斑中心凹上方出血较少(P < 0.001)与较好视力相关。
核心结论
- 非年龄相关性黄斑变性病因且黄斑中心凹上方出血较少,可预测接受玻璃体切除术联合视网膜下组织型纤溶酶原激活剂及气体填充治疗的黄斑中心凹下出血患者获得更好结局。
研究设计与样本
- 回顾性非对照干预性病例系列,纳入77例患者共78只眼。
主要发现
- 84.6%眼黄斑中心凹下出血病因为年龄相关性黄斑变性。
- 91.5%眼在术后2个月内实现黄斑中心凹下出血部分或完全移位。
- 视力从术前20/1,449提高至平均随访6.3个月时20/390,约相当于Snellen视力提高5行(P < 0.001)。
- 较好视力与无年龄相关性黄斑变性(P = 0.02)及黄斑中心凹上方出血较少(P < 0.001)相关。
- 最终视力与黄斑中心凹下出血面积(P = 0.17)、抗凝药使用(P = 0.14)及光学相干断层扫描显示椭圆体带可见(P = 0.64)无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To study the prognostic factors and clinical outcomes of patients who underwent pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and gas tamponade for the treatment of subfoveal hemorrhage (SFH). METHODS: A retrospective noncomparative interventional case series. RESULTS: Seventy-eight eyes from 77 patients were included. A total of 84.6% of eyes developed SFH from age-related macular degeneration. Partial or complete displacement of the SFH was achieved in 91.5% of eyes within 2 months of surgery. Visual acuity improved from 20/1,449 preoperatively to 20/390 after a mean follow-up time of 6.3 months, corresponding to approximately 5 lines of Snellen acuity improvement (P < 0.001). Better visual acuity was associated with the absence of age-related macular degeneration (P = 0.02) and less hemorrhage superior to the fovea (P < 0.001). Final visual acuity was not associated with the area of SFH (P = 0.17), use of anticoagulants (P = 0.14), or visibility of the ellipsoid layer by optical coherence tomography (P = 0.64). Nine patients (11.5%) developed a recurrence of SFH within the follow-up period. Recurrence of SFH was not associated with concurrent anticoagulant therapy (P = 0.52). CONCLUSION: An etiology other than age-related macular degeneration with less hemorrhage superior to the fovea predicts a better outcome in patients with SFH treated with pars plana vitrectomy, subretinal tissue plasminogen activator, and gas tamponade.
引用
- Plemel DJA, Lapere SRJ, Rudnisky CJ, et al. VITRECTOMY WITH SUBRETINAL TISSUE PLASMINOGEN ACTIVATOR AND GAS TAMPONADE FOR SUBFOVEAL HEMORRHAGE: Prognostic Factors and Clinical Outcomes. Retina. 2019. PMID: 29135798. doi:10.1097/IAE.0000000000001931
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。